The 171 references in paper O. Rosenberg A., О. Розенберг А. (2007) “Лёгочный сурфактант и его применение при заболеваниях лёгких // Lung Surfactant and Its Use in Lung Diseases” / spz:neicon:reanimatology:1089

1
King R. J., Clements J. A.Surface active materials from dog lung: composition and physiological correlations. Am. J. Physiol. 1972; 223: 715—726.
(check this in PDF content)
2
Avery M. E., Mead J.Surface properties in relation to atelectasis and hyaline membrane disease. Am. J. Dis. Child. 1959; 97: 517—523.
(check this in PDF content)
3
Gross N. K., Barnes E., Narine K. R.Recycling of surfactant in black and beige mice: pool sizes and kinetics. J. Appl. Physiol. 1988; 64: 1027—1025.
(check this in PDF content)
4
Bangham, A. D.Artificial lung expanding compound (ALECtm). In: Lasic, Papahajopoulos, (eds.) Medical applications of liposomes: 1998: Elsevier science. 455—452.
(check this in PDF content)
5
Iwaarden F. J., van Golde L. M. J.Pulmonary surfactant and lung defense. In: Robertson B., Taeusch H. W., (eds.) Surfactant therapy for lung disease. Lung biology in health and disease. N. Y.: 1995: Marcel Dekker Inc.; 84. 75—84.
(check this in PDF content)
6
Ashbaugh D. G., Bigelow D. B., Petty T. L. et al.Acute respiratory distress in adults. Lancet 1967; 2: 319—323.
(check this in PDF content)
7
Lewis J. F., Jobe A. H.Surfactant and the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 1993; 147: 218—233.
(check this in PDF content)
8
Schmidt R., Meier U., Yabut=Perez M. et al.Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and pneumonia. Am. J. Resp. Crit. Care Med. 2001; 163: 95—100.
(check this in PDF content)
9
Baughman R. P., Stein E., MacGee J. et al.Changes in fatty acids in phospholipids of the bronchoalveolar fluid in bacterial pneumonia and in adult respiratory distress syndrome. Clin. Chem. 1984; 30: 521—525.
(check this in PDF content)
10
Baughman R. P., Sternberg R., Hull W. et al.Decreased surfactant protein A in patients with bacterial pneumonia. Am. Rev. Respir. Dis. 1987; 147: 653—658.
(check this in PDF content)
11
Gunther A., Siebert C., Schmidt R. et al. Surfactant alterations in severe pneumonia, ARDS and cardiogenic lung edema. Am. J. Resp. Crit. Care Med. 1996; 153: 176—184.
(check this in PDF content)
12
Lewis J., Veldhuizen R. The role of surfactant in pneumonia and sepsis. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 55—57.
(check this in PDF content)
13
Bredow C., Birrer P., Griese M.Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis. Eur. Respir. J. 2001; 17: 716—724.
(check this in PDF content)
14
Griese M., Birrer P., Demirsoy A.Pulmonary surfactant in cystic fibrosis. Eur. Respir. J. 1997; 10: 1983—1997.
(check this in PDF content)
15
McCormack F. X., King T. E., Voelker D. R. et al.Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A. Am. Rev. Respir. Dis. 1991; 144: 160—169.
(check this in PDF content)
16
Robinson P. S., Watters L. C., King T. E. et al.Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage fluid phospholipids. Am. Rev. Respir. Dis. 1988; 137: 585—592.
(check this in PDF content)
17
Oyarzun M. J., Stevens P., Clemens J. A.Effect of lung collapse on alveolar surfactant in rabbits subjected to unilateral pneumothorax. Exp. Lung Res. 1989; 15: 90—96.
(check this in PDF content)
18
Hallman M., Maasita P., Kivisaari L. et al.Changes in surfactant in bronchoalveolar lavage fluid after hemithorax irradiation in patients with mesothelioma. Am. Rev. Respir. Dis. 1990; 141: 998—1007.
(check this in PDF content)
19
Ackerman S. J., Kwatia M. A., Doyle C. B. et al.Hydrolysis of surfactant phospholipids catalyzed by phospholipase A2 and eosinophil lysophospholipases causes surfactant dysfunction: a mechanism for small airway closure in asthma. Chest 2003; 123: 355—361.
(check this in PDF content)
20
Cheng G., Ueda T., Numao T. et al.Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur. Respir. J. 2000; 16: 831—835.
(check this in PDF content)
21
Haczku A., Atochina E. N., Tomer Y. et al.The late asthmatic response is linked with increased surface tension and reduced surfactant protein B in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2002; 283: 755—760.
(check this in PDF content)
22
Hohlfeld J., Ahlf K., EnhorningG. et al.Dysfunction of pulmonary surfactant in asthmatics after segmental allergen challenge. Am. J. Respir. Crit. Care Med. 1999; 159: 1803—1809.
(check this in PDF content)
23
Hohlfeld J. M., Schmiedl F., Erpenbeck V. J. et al.Eosiniphil cationic protein (ECP) alters pulmonary structure and function in asthma. J. Allergy Clin. Immunol. 2004; 113: 496—502.
(check this in PDF content)
24
Wang J. Y., Shieh C. C., Yu C. K. et al.Allergen-induced bronchial inflammation is associated with decreased levels of surfactant proteins A and D in a murine model of asthma. Clin. Exp. Allergy 2001; 31: 652—662.
(check this in PDF content)
25
Wright S. M., Hockey P. M., Enborning G. et al. Altered airway surfactant phospholipids composition and reduced lung function in asthma. J. Appl. Physiol. 2000; 89: 1283—1292.
(check this in PDF content)
26
Devendra G. Spragg R. G.Lung surfactant in subacute pulmonary disease. Respiratory Res. 2002; 3: 19—30.
(check this in PDF content)
27
Günther A. et al. Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur. Respir. J. 1999; 14: 565—576.
(check this in PDF content)
28
Ерохин В. В.Морфофункциональное состояние клеток легких при туберкулезном воспалении. В кн.: Ерохин В. В., Романова Л. К. (ред.) Клеточная биология легких в норме и при патологии. Руководство для врачей. М.: Медицина; 2000. 496—518.
(check this in PDF content)
29
Rosenberg O., Bautin A., Osovskich V. et al.Surfactant therapy for acute and chronic lung diseases. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 78—78.
(check this in PDF content)
30
Fujiwara T., Maeta H., Chida S. et al.Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 1: 55—59.
(check this in PDF content)
31
Lachmann B.Surfactant replacement in acute respiratory failure: Animal studies and first clinical trials. In.: Lachmann B. (ed.) Surfactant replacement тherapy. N. Y.: Springer-Verlag; 1987. 212—220.
(check this in PDF content)
32
Spragg R. G.Current status of surfactant treatment of ARDS/ALI. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 88—90.
(check this in PDF content)
33
Gregory T. J., Gadek J. E., Weiland J. E. et al.Survanta supplementation in patients with acute respiratory distress syndrome (ARDS). Am. J. Resp. Crit. Care Med. 1994; 49: 125—131.
(check this in PDF content)
34
Rosenberg O. A., Bautin A. E., Osovskich V. V. et al.When to start surfactant therapy (ST-therapy) of acute lung injury? Eur. Respir. J. 2001; 18 (Suppl. 38): 153, 7s.
(check this in PDF content)
35
Anzueto A., Baughman R., Guntupalli K. K. et al. Aerosolized surfactant in adults with septic-induced acute respiratory distress syndrome. N. Eng l. J. Med. 1996; 334: 1417—1421.
(check this in PDF content)
36
Bonсˆuk=Dayanikli P., Taeusch W. H.Essential and nonessential constituents of exogenous surfactants. In: Robertson, B. Taeusch, H. W. (eds.) Surfactant therapy for lung disease. Lung biology in health and disease. 84. N. Y.; 1995: Marcel Dekker, Inc. 217—238.
(check this in PDF content)
37
Günther A., Ruppert C., Schmidt R. et al. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir. Res. 2001; 2 (6): 353—364.
(check this in PDF content)
38
Sanders R. L.The composition of pulmonary surfactant. In: Farrell P. M. (ed.) Lung development: вiological and сlinical рerspectives. N. Y.: Academic Press; 1982. 1. 193—210.
(check this in PDF content)
39
Possmayer F. A proposed nomenclature for pulmonary surfactant-associated proteins. Am. Rev. Respir. Dis. 1988; 138: 990—998.
(check this in PDF content)
40
Persson A., Chang D., Rust D. et al.Purification and biochemical characterization of CP4 (SP-D), a collagenous surfactant-associated protein. Biochemistry 1989; 28: 6361—6367.
(check this in PDF content)
41
Weaver T. E., Whitsett J. A.Function and regulation of expression of pulmonary surfactant-associated proteins. Biochem. J. 1991; 273: 249—264.
(check this in PDF content)
42
Goerke J., Clements J. A.Alveolar surface tension and lung surfactant. In: Handbook of рhysiology. The Respiratory system. Mechanics of вreathing. 3 Am. Phisiol. Soc. Bethesda; 1986. Sect. 3. P I. 247—263.
(check this in PDF content)
43
Schurch S., Bachofen H.Biophysical aspects in the design of a therapeutic surfactant. In: Rodertson B., Taeush H. W., (eds.) Surfactant therapy for lung disease. Lung biology in health and disease. 84. N. Y.: Marcel Dekker Inc; 1995. 3—26.
(check this in PDF content)
44
Horie T., Hildebrandt J.Dynamic compliance, limit cycles and static equilibria of excised cat lung. J. Appl. Physiol. 1971; 31: 423—428.
(check this in PDF content)
45
Mead J., Collier C. Relation of volume history of lungs to respiratory mechanics in anesthetized dogs. J. Appl. Physiol. 1959; 14: 669—675.
(check this in PDF content)
46
Rosenberg O., Seiliev A., Zhuikov.Lung Surfactant: Correlation beween biophysial charactrisic, composition, and therapeutic effiacy. In: Gregory Gregoriadis, (ed.) Liposome тechnology. Taylor and Francis; 2006. 3ed, 3, сh. 17. 317—345.
(check this in PDF content)
47
Bachofen H. et al.Relations among alveolar surface tension, surface area, volume and recoil pressure. J. Appl. Physiol. 1987; 62: 1878-1891.
(check this in PDF content)
48
Schürch S., Goerke J., Clements J. A.Direct determination of volumeand time-dependence of alveolar surface tension in excised lungs. Proc. Natl. Acad. Sci. USА 1978; 75: 3417—3420.
(check this in PDF content)
49
Bachofen H. et al.Experimental hydrostatic pulmonary edema in rabbit lungs. Morphology. Am. Rev. Respir. Dis. 1993; 147: 989—996.
(check this in PDF content)
50
Bachofen H., Schürch, S., Weibel I. R. Experimental hydrostatic pulmonary edema in rabbit lungs. Barrier lesions. Am. Rev. Respir. Dis. 1993; 147: 997—1006.
(check this in PDF content)
51
LaForce F. M., Kelley W. J., Huber J. L.Inactivation of staphylococci by alveolar macrophages with preliminary observations on the importance of alveolar lining material, Am. Rev. Respir. Dis. 1973; 108: 783—789.
(check this in PDF content)
52
Wollmer P., Jonson B., Lachmann B.Evaluation of lung permeability. In: Robertson B., Taeusch, H. W., (eds.) Surfactant therapy for lung disease. Lung biology in health and disease. N. Y.: Marcel Dekker, Inc.; 1995; 84. 199—215.
(check this in PDF content)
53
Hohlfeld J., Fabel H., Hamm H.The role of pulmonary surfactant in obstructive airway disease. Eur. Respir. J. 1997; 10: 482—491.
(check this in PDF content)
54
Hohlfeld J. M.The role of pulmonary surfactant in asthma. Major components of surfactant (functions). Respir. Res. 2002; 3: 4—12.
(check this in PDF content)
55
Bates S. R., Ibach P. B, Fisher A. B, Phospholipids co-isolated with rat surfactant protein C account for the apparent protein-enhanced uptake of liposomes into lung granular pneumocytes. Exp. Lung Res. 1989; 15: 695—708.
(check this in PDF content)
56
Goerke J.Pulmonary surfactant: functions and molecular composition. Biochim. Biophys. Acta 1998; 1408: 79—89.
(check this in PDF content)
57
Cocksgutt A., Absolom D., Possmayer F.The role of palmitic acid in pulmonary surfactant: enhancement of surface activity and prevention of inhibition by blood proteins. Biochim. Biophys. Acta 1991; 1085: 248—256.
(check this in PDF content)
58
Holm B. A., Venkitaraman A. R., Enchorning G. et al.Biophysical inhibition of synthetic lung surfactants. Chem. Phys. Lipids 1990; 52: 243—250.
(check this in PDF content)
59
Longo M. L., Bisango A. M., Zasadzinski J. et al.A function of lung surfactant protein SP-B. Science 1993; 261: 453—456.
(check this in PDF content)
60
Tanaka, Y., Takei T., Aiba T. et al.Development of synthetic lung surfactants. J. Lipid Res. 1986; 27: 475—485.
(check this in PDF content)
61
Orgeig S., Daniels C. B.The roles of cholesterol in pulmonary surfactant: insights from comparative and evolutionary studies. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2001; 129: 75—89.
(check this in PDF content)
62
Bunt J. E. H.Surfactant therapy stimulates endogenous surfactant synthesis in premature infants. Crit. Care Med. 2000; 28: 3383.
(check this in PDF content)
63
Ikegami M.SP-B protects lung from inflammation. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 45—47.
(check this in PDF content)
64
Miles P. R., Bowman L., Rao K. M. et al.Pulmonary surfactant inhibits LPS-induced nitric oxide production by alveolar macrophages. Am. J. Physiol. 1999; 276 (1P. 1): 186—196.
(check this in PDF content)
65
Iwaarden J. F., Claassen E., Jeurissen S. H. et al. Alveolar macrophages, surfactant lipids, and surfactant protein B regulate the induction of immune responses via the airways. Am. J. Respir. Cell Mol. Biol. 2001; 24 (4): 452—458.
(check this in PDF content)
66
Floros J., Phelps D. S., Pison U. et al. Pulmonary surfactant-update on function, molecular biology and clinical implications. Cur. Respiratory Med. Rev. 2005; 1 (1): 77—84
(check this in PDF content)
67
Crouch E., Wright. J. R.Surfactant proteins A and D and pulmonary host defense. Ann. Rev. Physiol. 2001; 63: 521—534.
(check this in PDF content)
68
Phelps D. S.Surfactant regulation of host defense function in the lung: a question of balance. Pediatr. Pathol. Mol. Med. 2001; 20: 269—274.
(check this in PDF content)
69
Erpenbeck V. J., Malherbe D. C., Sommer S. et al.Surfactant protein D regulates phagocytosis of Grass pollen-derived starch granules by alveolar macrophages. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 31—32.
(check this in PDF content)
70
Hawgood S. The hydrophilic surfactant protein SP-A: Molecular biology, structure and function. In: Robertson B., Van Golde L. M. G., Batenburg J. J., (eds.) Pulmonary surfactant: From molecular biology to clinical practice. Amsterdam: Elsevier; 1992. 33—54.
(check this in PDF content)
71
Wright J. R.Immunomodulatory functions of surfactant. Physiol Rev. 1997; 77: 931—942.
(check this in PDF content)
72
Wright J. R.Surfactant: A pulmonary link between innate and adaptive immunity. Appl. Cardiopulm. Pathophysiol. 2004; 13: 104—105.
(check this in PDF content)
73
Clark H., Palaniyar N., Strong P. et al.Surfactant protein reduces alveolar macrophage apoptosis in vivo. J. Immunol. 2002; 169 (6): 2892—2899.
(check this in PDF content)
74
Clark H. W., Palaniyar N., Hawgood S. et al.A recombinant fragment of human surfactant protein D reduces alveolar macrophage apoptosis and pro-inflammatory cytokones in mice developing pulmonary emphysema. Ann. N. Y. Acad. Sci. 2003; 1010: 113—116.
(check this in PDF content)
75
Kaplan J. H., Casey J. A., Savani R. C. et al.Differential response of collectin deficient mouse models to bleomycin induced lung injury. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 51—52.
(check this in PDF content)
76
Lewis J., Veldhuizen R.The role of surfactant in the pathophysiology of acute lung injury. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 53—55.
(check this in PDF content)
77
Clark J. C., Wert S. E., Bachurski C. J. et al.Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc. Natl. Acad. Sci. USA 1995; 92 (17): 7794—7798.
(check this in PDF content)
78
Nogee L. M., Garnier G., Dietz H. C. et al.A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J. Clin. Invest. 1994; 93 (4): 1860—1863.
(check this in PDF content)
79
Melton K. R., Nesslein L. L., Ikegami M. et al. SP-B deficiency causes respiratory failure in adult mice. Am. J. Physiol. 2003; 285: 543—549.
(check this in PDF content)
80
Cochrane C. G. A critical examination of the role of SP-B in alveolar expansion, Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 27—29.
(check this in PDF content)
81
Cruz A., Vazquez L., Bernardinjo J. et al.Analysis by scanning force microscopy of the micro- and nano-structure of Langmuir-Blodgett pulmonary surfactant films. Appl. Cardiopulm. Pathophysiol. 2004; 13: 30—31.
(check this in PDF content)
82
Cruz A. et al. Effect of pulmonary surfactant protein SP-B on the microand nanostructure of phospholipids films. Biophys. J. 2004; 86: 308—310.
(check this in PDF content)
83
Na Nkorn P., Flach C. R., Mendelsohn R. et al.The influence of truncated surfactant-protein C (SP-C17) on the surface properties of lipidmonolayers at the air-water interface. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 62—63.
(check this in PDF content)
84
Weaver T. E., Conkright J. J.Function of surfactant proteins B and C. Annu. Rev. Physiol. 2001; 63: 555—578.
(check this in PDF content)
85
Cotton R. B., Olsson T.Lung mechanics in respiratory distress syndrome. In: Robertson B., Taeusch H. W. (eds.) Surfactant therapy for lung disease. Lung biology in health and disease. N. Y.: Marcel Dekker, Inc.; 1995; 84. 121—150.
(check this in PDF content)
86
Floros J., Veletza V., Kotikalapudi P. et al.Dinucleotide repeats in the human surfactant protein B gene and respiratory distress syndrome. Biochem. J. 1995; 305: 583—590.
(check this in PDF content)
87
Nogee L. M., deMello D. E., Dehner L. P. et al.Deficiency of pulmonary surfactant protein B in alveolar proteinosis. N. Engl. J. Med. 1993; 328: 406—410.
(check this in PDF content)
88
Рейниш М. С., Розенберг О. А. Быстрый метод определения фосфолипидов в амниотической жидкости. Лаб. дело 1978; (2): 98—100.
(check this in PDF content)
89
Bernard G. R. et al.The American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am. J. Respir. Crit. Care Med. 1994; 149: 818—821.
(check this in PDF content)
90
Gregory T. J., Longmore W. J., Moxley M. A. et al.Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J. Clin. Invest. 1991; 88: 1976—1981.
(check this in PDF content)
91
Hallman M., Spragg R., Harrell J. H. et al.Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity and plasma myoinositol. J. Clin. Invest. 1982; 70: 673—683.
(check this in PDF content)
92
Pison U., Seeger W., Buchhorn R. et al. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am. Rev. Respir. Dis. 1989; 140: 1033—1039.
(check this in PDF content)
93
Green K. E., Wright J. R., Steinberg K. R. et al. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am. J. Resp. Crit. Care Med. 1999; 160: 843—1850.
(check this in PDF content)
94
Lewis J. F., Veldhuizen R., Possmayer F. et al.Altered alveolar surfactant is an early marker of acute lung injury in septic adult sheep. Am. J. Resp. Crit. Care Med. 1994; 150 (1): 123—130.
(check this in PDF content)
95
Veldhuizen R., McCaig L. A., Akino T. et al.Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome. Am. J. Resp. Crit. Care Med. 1995; 152: 1867—1871.
(check this in PDF content)
96
Cockshutt A. M., Weitz J., Possmayer F.Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 1990; 29: 8424—8429.
(check this in PDF content)
97
Fuchimukai T., Fujiwara T., Takahashi A.Artificial pulmonary surfactant inhibition by proteins. J. Appl. Physiol. 1987; 62: 429—437.
(check this in PDF content)
98
Seeger W., Stohr G., Wolf H. R.Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J. Appl. Physiol. 1985; 58: 326—338.
(check this in PDF content)
99
Holm B. A., Notter R. H.Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J. Appl. Physiol. 1987; 63: 1434—1442.
(check this in PDF content)
100
Seeger W., Thede C., Gunter A. et al. Surface properties and sensitivity to protein-inhibition of a recombinant apoprotein C-based phospholipids mixture in vitro-comparison to natural surfactant. Biochim. Biophys. Acta 1991; 1081: 45—52.
(check this in PDF content)
101
Seeger W., Gunther A., Thede C. Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants. Am. J. Physiol. 1992; 262: 286—291.
(check this in PDF content)
102
Venkitaraman A. R., Gunther A., Thede C. et al.Biophysical inhibition of synthetic phosphilipid-lung surfactant apoprotein admixtures by plasma proteins. Chem. Phys. Lipids 1991; 57: 49—57.
(check this in PDF content)
103
Gunther A., Kalinovski M., Rosseau S. et al.Surfactant incorporation markedly alters mechanical properties of a fibrin clot. Am. J. Respir. Cell Mol. Biol. 1995; 13: 712—718.
(check this in PDF content)
104
Seeger W., Elssner A., Gunter A. et al.Lung surfactant phospholipids associate with polymerizing fibrin: loss of surface activity. Am. J. Respir. Cell Mol. Biol. 1993; 9: 213—220.
(check this in PDF content)
105
Gunther A., Markart P., Kalinowski M. et al.Cleavage of surfactantincorporated fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity. Am. J. Respir. Cell Mol. Biol. 1999; 21: 738—745.
(check this in PDF content)
106
Schermuly R. T., Gunter A., Ermert M. et al. Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation. Am. J. Physiol. Lung Cell Mol. Physiol. 2001; 280: 792—800.
(check this in PDF content)
107
Baker C. S., Evans T. W., Randle B. J. et al.Damage to surfactant-specific protein in acute respiratory distress syndrome. Lancet 1999; 353: 1232—1235.
(check this in PDF content)
108
Pison U., Obertacke U., Brand M. et al.Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J. Trauma 1990; 30: 19—26.
(check this in PDF content)
109
Petty T. L., Silvers G. W., Paul G. et al.Abnormalities in lung elastic properties and surfactant function in adult respiratory distress syndrome. Chest 1979; 75: 571—574.
(check this in PDF content)
110
Günter A., Schmidt R., Harold J. at al.Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact of biophysical and biochemical surfactant properties. Eur. Respir. J. 2002; 19: 797—804.
(check this in PDF content)
111
Gregory T. J., Steinberg K. R., Spragg R. et al.Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am. J. Resp. Crit. Care Med. 1997; 155: 1309—1315.
(check this in PDF content)
112
Hohlfeld J. M.Potential role of surfactant in asthma. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 44—45.
(check this in PDF content)
113
Kurashima K., Fuimura M., Matsuda T., Kobauashi T. Surface activity of sputum from acute asthmatic patients. Am. J. Respir. Crit. Care Med. 1997; 155: 1254—1257.
(check this in PDF content)
114
Cheng G. et al. Compositional and functional changes of pulmonary surfactant in a guinea-pig model of chronic asthma. Respir. Med. 2001; 95: 180—186.
(check this in PDF content)
115
Liu M., Wang L., Enhorning G.Surfactant dysfunction develops when the immunized guinea-pig is challenged with ovalbumin aerosol. Clin. Exp. Allergy 1995; 25: 1053—1056.
(check this in PDF content)
116
Morley C. J. et al. Dry artificial lung surfactant and its effect on very premature babies. Lancet 1981; 1: 64—66.
(check this in PDF content)
117
Revak S. D., Merritt T. A., Hallman M. et al.The use of synthetic peptides in the formation of biophysically and biologically active pulmonary surfactants Pediatr. Res. 1991; 29: 460-465.
(check this in PDF content)
118
Häfner D., Germann P. =G., Hauschke D.Effects of rSP-C surfactant on oxygenation and histology in a rat-lung-lavage model of acute lung injury. Am. J. Respir. Crit. Care Med. 1998; 158: 270—276.
(check this in PDF content)
119
Баутин А. Е., Осовских В. В., Хубулава Г. Г. и др. Многоцентровые клинические испытания сурфактанта-BL для лечения респираторного дистресс-синдрома взрослых. Клинические исследования лекарственных средств в России 2002; (2): 18—23.
(check this in PDF content)
120
Curstedt T., Jornvall H., Berggren P. et al.Artificial surfactant based on different hydrophobic low-molecular — weight proteins. In: Lachmann B. (ed.) Surfactant replacement therapy in neonatal and adult respiratory distress syndrome. Berlin: Springer-Verlag; 1988. 332—337.
(check this in PDF content)
121
Hallman M. , Meritt T. A., Schneider H. et al.Isolation of human surfactant from amniotic fluid and pilot study of its efficacy in respiratory distress syndrome. Pediatrics 1983; 71: 473—482.
(check this in PDF content)
122
Розенберг О. А., Данилов Л. Н., Волчков В. А. и др. Фармакологические свойства и терапевтическая активность отечественных препаратов легочного сурфактанта. Бюл. эксперим. биол. и мед. 1998; 126 (10): 455—458.
(check this in PDF content)
123
Шаламов В. Ю., Веселова Н. Б., Миленин О. Б. и др.Эффективность отечественного сурфактанта из амниотической жидкости человека — Сурфактант-HL в комплексе интенсивной терапии новорожденных с РДС. Рос. вестн. перинатологии и педиатрии 1999; 44 (4): 29—34.
(check this in PDF content)
124
Розенберг О. А., Сейлиев А. А., Волчков В. А. и др.Легочные сурфактанты природного происхождения для лечения синдрома дыхательных расстройств новорожденных и взрослых. В кн.: Материалы конф. Актуальные проблемы создания новых лекарственных препаратов природного происхождения. СПб. — Валаам; 1998. 81—85.
(check this in PDF content)
125
Notter R. H., Egan E. A., Kwong M. S. et al. Lung surfactant replacement in premature lambs with extracted lipids from bovine lung lavage: effects of dose, dispersion technique and gestational age. Pediatr. Res. 1985; 19: 569—574.
(check this in PDF content)
126
Yu S. et al. Bovine pulmonary surfactant: chemical composition and physical properties. Lipids 1983; 18: 522—526.
(check this in PDF content)
127
Bligh E. G., Dayer W. J.A. rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959; 37: 911—916.
(check this in PDF content)
128
Bernhard W., Mottaghian J., Gebert A et al.Commercial versus native surfactants surface activity, molecular components, and the effect of calcium. Am. J. Respir. Crit. Care Med. 2000; 162: 1524—1533.
(check this in PDF content)
129
Rudiger M., Tolle A., Meier W. et al.Naturally derived commercial surfactants differ in composition of surfactant lipids and in surface viscosity. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005; 288: L379—L380.
(check this in PDF content)
130
Taeusch H. W., Karen L. U., Ramierez=Schrempp D.Improving pulmonary surfactants. Acta Pharmacol. Sin. 2002; 11: 15—18.
(check this in PDF content)
131
Gunther A., Seeger W.Resistance to surfactant inactivation. In: Robertson B., Taeusch H. W. (eds.) Surfactant therapy for lung disease. Lung biology in health and disease. N. Y.: Marcel Dekker, Inc.; 1995; 84. 269—279.
(check this in PDF content)
132
Seeger W., Grube C., Gunter A. et al. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur. Respir. J. 1993; 6: 971—977.
(check this in PDF content)
133
Arnold C. et al. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics 1996; 97: 1—11.
(check this in PDF content)
134
Halliday H. L. Natural vs synthetic surfactant in neonatal respiratory distress syndrome Drugs 1996; 51: 226—232.
(check this in PDF content)
135
Любименко В. А., Шабалов Н. П., Иванов Д. О.Результаты заместительной терапии натуральным препаратом куросурф у новорожденных детей с тяжелыми поражениями легких. Детская больница 2002; (2): 38—44,
(check this in PDF content)
136
Мостовой А. В., Наумов Д. Ю.Профилактическое и терапевтическое введение куросурфа недоношенным новорожденным с низкой и экстремально низкой массой тела с последующим переводом на неинвазивную вентиляцию легких: влияние на неврологический исход (пилотное исследование). В кн.: Материалы 5 Съезда Рос. ассоциации специалистов перинатальной медицины. М.; 2005. 134—136.
(check this in PDF content)
137
Русанов С. Ю., Черданцева Г. А., Антонов А. Г. и др.Сравнительная эффективность эндотрахеального ингаляционного и микроструйного введения сурфактанта-BL в комплексном лечении тяжелого РДС у недоношенных новорожденных. Рос. вестн. перинатологии и педиатрии 2003 (1): 26—31.
(check this in PDF content)
138
Романенко К. В., Романенко В. А., Аверин А. П. и др.Оценка эффективности отечественного сурфактанта в комплексном лечении дыхательной недостаточности у новорожденных детей. Рос. вестн. перинатологии и педиатрии 2001; (1): 22—25.
(check this in PDF content)
139
Затовка Г. Н., Дугинова С. А., Сафаров А. А. и др.Лечение респираторного дистресс-синдрома у новорожденных с применением сурфактанта-BL. Анестезиология и реаниматология 2006; (1): 38—43.
(check this in PDF content)
140
Lachmann B.Open up the lung and keep the lung open. Intensive Care Med. 1992; 13: 319—324.
(check this in PDF content)
141
Walmrath D., Grimminger F., Pappert D. et al.Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur. Respir. J. 2002; 19: 805—810.
(check this in PDF content)
142
Spragg R. G., Gilliard N., Richmann P. et al.Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 1994; 105: 195—202.
(check this in PDF content)
143
Walmrath D., Gunter A., Ghofrani H. A et al.Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am. J. Resp. Crit. Care Med. 1996; 154: 57—62.
(check this in PDF content)
144
Willson D. F., Zaritsky A., Bauman L. A et al.Instillation of calf lung surfactant extract (Calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Crit. Care Med. 1999; 27: 188—195.
(check this in PDF content)
145
Spragg R. G., Zewis J. F., Walmrathe H.=D. et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N. Engl. J. Med. 2004; 351: 884—889.
(check this in PDF content)
146
Цыбулькин Э. К., Розенберг А. O., Ceйлиев А. А. и др.Опыт применения отечественного препарата легочного сурфактанта для лечения синдрома дыхательных расстройств взрослых и тяжелых пневмоний у детей. Анестезиология и реаниматология 1999; (2): 26—32.
(check this in PDF content)
147
Розенберг О. А., Баутин А. Е., Осовских В. В. и др.Сурфактант-терапия синдрома острого повреждения легких. В кн.: 2 Междунар. конгр. по респираторной поддержке. Красноярск; 2005. 97—98.
(check this in PDF content)
148
Anzueto A., Baughman R. P., Yuntupalli K. K. et al.Aerosolized surfactant in adults with septi-induced acute respiratory distress syndrome. N. Engl. J. Med. 1996; 334: 1417—1421.
(check this in PDF content)
149
Anzueto A.Exogenous surfactant in acute respiratory distress syndrome: more is better. Eur. Respir. J. 2002; 19: 787—789.
(check this in PDF content)
150
Wiswell T. E., Smith R. M., Katz L. B. et al.Bronchopulmonary segmental lavage with Surfaxin (KL4-Surfactant) for acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 1999; 160: 1188—1195.
(check this in PDF content)
151
Greenhalgh T.How to read a paper: The basics of evidence based medicine. 2nd ed. L.: BMJ Books; 2001.
(check this in PDF content)
152
Liolios A. Evidence-based medicine in intensive care unit. In: A debate 23rd. Int. sympos. of intensive care and emergency medicine. Progr. and abstracts. Brussels; 2003. 18—21.
(check this in PDF content)
153
Marini J. J.Evidence-based medicine in intensive Care Unit. In: Ibid 18—21.
(check this in PDF content)
154
Marini J. J.Advances in the understanding of acute respiratory distress syndrome: summarizing a decade of progress. Curr. Opin. Crit. Care 2004; 10 (4): 265—271.
(check this in PDF content)
155
Osovskikh V., Seiliev A., Rosenberg O.Exogenous surfactant: a potent drug for gastric content aspiration? Eur. Respir. J. 2002; 20: 336—336.
(check this in PDF content)
156
Osovskikh V., Seiliev A., Rosenberg O.ARDSp and ARDSexp: different responses to surfactant administration. Eur. Respir. J. 2003; 22: 551—551.
(check this in PDF content)
157
Tarasenko M., Shpakov Ig., Kallistov D. et al.Surfactant therapy — the real chance to survive for patients with severe inhalation injury. Eur. Respir. J. 2004; 24, (Suppl. 48): 4127 (677 s).
(check this in PDF content)
158
Баутин А. Е., Хубулава Г. Г., Оссовских В. В., Розенберг О. А.Результаты применения природного легочного сурфактанта при респираторном дистресс-синдроме после операций на открытом сердце. Анестезиология и реаниматология 2003; (4): 55—57.
(check this in PDF content)
159
Козлов И. А., Попцов В. Н.Сочетанная терапия оксидом азота и сурфактантом-BL при остром респираторном дистресс-синдроме после операций с искусственным кровообращением. Общая реаниматология 2005; 1: 15—19.
(check this in PDF content)
160
Walmrath D., De Vaal J. B., Bruining H. P. et al.Treatment of ARDS with a recombinant SP-C (rSP-C) based synthetic surfactant. Am. J. Resp. Crit. Care Med. 2000; 161: A379.
(check this in PDF content)
161
Власенко А. В., Остапченко Д. А. Мороз B. B. и др. Применение сурфактанта-BL у взрослых больных с острым респираторным дистресс-синдромом различного генеза. Общая реаниматология 2005; 1: 21—29.
(check this in PDF content)
162
Taeusch H. W., Keough K. M. W., Williams M. et al.Characterization of bovine surfactant for infants with respiratory distress syndrome. Pediatrics 1986; 77: 572—581
(check this in PDF content)
163
Mikawa K. et al.Selective intrabronchial instillation of surfactant in a patient with pneumonia: a preliminary report. Eur. Respir. J. 1993; 6: 1563—1566.
(check this in PDF content)
164
Dulkys Y. et al.Natural porcine surfactant augments airway inflammation after allergen challenge in patients with asthma. Am. J. Respi r. Crit. Care Med. 2004; 169: 578—581.
(check this in PDF content)
165
Kurashima K. A pilot study of surfactant inhalation in the treatment of asthmatic attack. Allerugi 1991; 40: 160—168.
(check this in PDF content)
166
Oetomo S. B. et al.Surfactant nebulization does not alter airflow obstruction and bronchial responsiveness to histamine in asthmatic children. Am. J. Respir. Crit. Care Med. 1996; 153: 1148—1153.
(check this in PDF content)
167
Ловачева О. В., Черниченко Н. В., Евгущенко Г. В. и др.Результаты применения препарата сурфактанта в комплексной терапии больных деструктивным туберкулезом легких. Проблемы туберкулеза и болезней легких 2006; (10): 12—17.
(check this in PDF content)
168
Erokhin V. V. Chenichenko N. V. Lepekha L. N. et al. Peculiarities of macrophagal composition of bronchial washings in destructive TB patients after using surfactant-BL (S-BL). Eur. Respir. J. 2003; 22: (Suppl. 40): 340.
(check this in PDF content)
169
Rosenberg O., Erochin V. O., Lovacheva O. V. et al. The application of the liposome form of lung surfactant (Surfactant-BL) for complex treatment of multi-drug resistant tuberculosis. Jn: 6th international conference Liposome advances. L. 2003. 61—62.
(check this in PDF content)
170
Anzueto A., Jubran A., Ohar J. A. et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA 1997; 278: 1426—1429.
(check this in PDF content)
171
Lovacheva O. V., Nataly V., Chemichenko L. N. et al. Use of surfactantBL (S-BL) in complex treatment of pulmonary TB patients. Eur. Respir. J. 2003; 22: 521—521. Поступила 30.11.06
(check this in PDF content)